

Versatile by design

Learn how single cell technologies enable profiling immunotherapy response



MA900 cell sorter

SONY



Comment on "Engineering Antibody Heavy Chain CDR3 to Create a Phage Display Fab Library Rich in Antibodies That Bind Charged Carbohydrates"

This information is current as of June 22, 2021.

Alexander H. Lucas and Donald C. Reason

J Immunol 2009; 182:5160-5161; ;

doi: 10.4049/jimmunol.0990032

<http://www.jimmunol.org/content/182/9/5160.1>

References This article **cites 9 articles**, 4 of which you can access for free at: <http://www.jimmunol.org/content/182/9/5160.1.full#ref-list-1>

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at: <http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at: <http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: <http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2009 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Response to the Comments on “Dendritic Cells and Monocyte/Macrophages That Create the IL-6/APRIL-Rich Lymph Node Microenvironment Where Plasmablasts Mature”

In their letter to the editor, Belnoue et al. highlight an important difference between the cell types in mouse and human that produce APRIL at sites of Ab production. Belnoue et al. report an immunohistological study of APRIL expression in human lymph nodes where neutrophils are comfortably the highest constitutive producers of APRIL protein. This contrasts with our study of mouse lymph nodes published in the February 15, 2009 issue of *The Journal of Immunology*, where the main source of APRIL mRNA was found to be Gr1⁺CD11b^{high}F4/80⁺ monocyte/macrophages recruited after immunization with alum-precipitated OVA (1). In addition, in our mouse model, Gr1^{high}CD11b^{high} neutrophils were the only nonstromal source of BAFF (Blys) mRNA identified in the lymph node. Other studies in humans have demonstrated the ability of neutrophils to produce BAFF (2). BAFF is more active in B cell homeostasis, while APRIL is particularly associated with plasma cell maturation and survival. These data point to human neutrophils' capacity to influence B cell biology at a number of levels through their production of BAFF and/or APRIL, whereas in mice these different functions seem to involve distinct cell subsets. This apparent discrepancy may prove useful in understanding the mechanisms underlying the regulation of BAFF/APRIL expression during the differentiation of cells of myeloid lineage. It should be noted that in humans, in addition to neutrophils, a number of other cells including CD14⁺ blood monocyte-derived nurse-cells (3), osteoclasts, monocyte/macrophages (4), and dendritic cells can deliver an effective APRIL signal to plasma cells involved in myeloma or autoimmune diseases (see Ref. 5 for review). Untangling the heterogeneity in the cellular composition of plasma cell sustaining niches as well as their functional specificities is an important issue that requires further studies.

Elodie Mohr, Karine Serre, and Ian MacLennan

Medical Research Council Centre for Immune Regulation
Institute for Biomedical Research
College of Medical and Dental Sciences
School of Immunity and Infection,
Edgbaston, Birmingham, United Kingdom

References

- Mohr, E., K. Serre, R. A. Manz, A. F. Cunningham, M. Khan, D. L. Hardie, R. Bird, and I. C. MacLennan. 2009. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. *J. Immunol.* 182: 2113–2123.
- Scapini, P., F. Bazzoni, and M. A. Cassatella. 2008. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. *Immunol. Lett.* 116: 1–6.

- Nishio, M., T. Endo, N. Tsukada, J. Ohata, S. Kitada, J. C. Reed, N. J. Zvaifler, and T. J. Kipps. 2005. Nurse-like cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1 α . *Blood* 106: 1012–1020.
- Moreaux, J., F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaulke, V. Pantescio, J. De Vos, E. Jourdan, A. Jauch, et al. 2005. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. *Blood* 106: 1021–1030.
- Mackay, F., P. A. Silveira, and R. Brink. 2007. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. *Curr. Opin. Immunol.* 19: 327–336.

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990034

Comment on “Engineering Antibody Heavy Chain CDR3 to Create a Phage Display Fab Library Rich in Antibodies That Bind Charged Carbohydrates”

In their report, Schoonbroodt et al. demonstrate the utility of using semisynthetic libraries for the isolation of anti-carbohydrate Abs specific for small glycan Ags and for self-glycans (1). However, they make several statements that are either incorrect or propagate commonly held misconceptions about Ab responses to carbohydrates. First, they state “Given the low immunogenicity of carbohydrates, immunization procedures often result in only a weak primary IgM response or no response at all.” Although murine responses to purified polysaccharides are often restricted to the IgM and IgG3 isotypes, there is a wealth of data from human studies showing that carbohydrate Ags such as purified bacterial capsular polysaccharides can elicit strong Ab responses of the IgG and IgA isotypes (2). Second, they state that “conventional hybridoma technology has generated anti-carbohydrate Abs of the IgM class, unsuitable for in vivo diagnostics or therapy.” Conventional hybridoma technology has been used to isolate human IgM, IgA, and IgG mAbs to a variety of bacterial polysaccharides following immunization with either plain or protein-conjugated polysaccharide (3–6). Third, in their *Discussion*, Schoonbroodt et al. make the statement “In reported sequences, L chains do not show any recognizable motifs; they are diverse and belong to both κ and λ families, suggesting that the L chain does not play a critical role in the selection of anti-carbohydrate Abs.” In fact, canonical L chain configurations have been demonstrated in murine α -1,3 dextran-specific myeloma proteins and mAbs (7), the human responses to the *Haemophilus influenzae* type b polysaccharide (8, 9) and the type 23F pneumococcal polysaccharide (10).

Alexander H. Lucas and Donald C. Reason

Center for Immunobiology and Vaccine Development
Children's Hospital Oakland Research Institute
Oakland, CA 94609

References

- Schoonbroodt, S., M. Steukers, M. Viswanathan, N. Frans, M. Timmermans, A. Wehnert, M. Nguyen, R. C. Ladner, and R. M. Hoet. 2008. Engineering antibody heavy chain CDR3 to create a phage display library rich in antibodies that bind charged carbohydrates. *J. Immunol.* 181: 6213–6221.
- Plotkin, S., W. Orenstein, and P. Offit, eds. 2008. *Vaccines*, 5th Ed. Saunders, Philadelphia.

3. Lucas, A. H., J. W. Larrick, and D. C. Reason. 1994. Variable region sequences of a protective human monoclonal antibody specific for the *Haemophilus influenzae* type b capsular polysaccharide. *Infect. Immun.* 62: 3873–3880.
4. Adderson, E. E., P. G. Shackelford, A. Quinn, P. M. Wilson, M. W. Cunningham, R. A. Insel, and W. L. Carroll. 1993. Restricted immunoglobulin V_H usage and VDJ combinations in the human response to *Haemophilus influenzae* type b capsular polysaccharide. Nucleotide sequences of monospecific anti-*Haemophilus* antibodies and polyspecific antibodies cross-reacting with self antigens. *J. Clin. Invest.* 91: 2734–2743.
5. Baxendale, H. E., Z. Davis, H. N. White, M. B. Spellerberg, F. K. Stevenson, and D. Goldblatt. 2000. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. *Eur. J. Immunol.* 30: 1214–1223.
6. Pinchuk, G. V., C. Nottenburg, and E. C. B. Milner. 1995. Predominant V-region configurations in the human antibody response to *Haemophilus influenzae* capsule polysaccharide. *Scand. J. Immunol.* 41: 324–330.
7. Schilling, J., B. Clevinger, and L. Hood. 1980. Amino acid sequences of homogeneous antibodies to dextran and DNA rearrangements in heavy chain V-region segments. *Nature* 283: 35–40.
8. Scott, M. G., D. L. Crimmins, D. W. McCourt, I. Zocher, R. Thiede, H. G. Zacha, and M. H. Nahm. 1989. Clonal characterization of the human antibody repertoire to *Haemophilus influenzae* type b polysaccharide III: a single V κ II gene and one of several J κ genes are joined by an invariant arginine to form the most common L chain V region. *J. Immunol.* 143: 4110–4116.
9. Lucas, A. H., R. J. Langley, D. M. Granoff, M. H. Nahm, M. Y. Kitamura, and M. G. Scott. 1991. An idiotypic marker associated with a germ-line encoded κ light chain variable region that predominates the vaccine-induced human antibody response to the *Haemophilus influenzae* b polysaccharide. *J. Clin. Invest.* 88: 1811–1818.
10. Zhou, J., K. R. Lottenbach, S. J. Barenkamp, A. H. Lucas, and D. C. Reason. 2002. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of *Streptococcus pneumoniae* type 23F. *Infect. Immun.* 70: 4083–4091.

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990032